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International standardization of criteria for the histologic diagnosis of
renal allograft rejection: The Banif working classification of kidney
transplant pathology. A group of renal pathologists, nephrologists, and
transplant surgeons met in Banif, Canada on August 2—4, 1991 to
develop a schema for international standardization of nomenclature and
criteria for the histologic diagnosis of renal allogralt rejection. Devel-
opment continued after the meeting and the schema was validated by
the circulation of sets of slides for scoring by participant pathologists.
In this schema intimal arteritis and tubulitis are the principal lesions
indicative of acute rejection. Glomerular, interstitial, tubular, and
vascular lesions of acute rejection and "chronic rejection" are defined
and scored 0 to 3+, to produce an acute and/or chronic numerical
coding for each biopsy. Arteriolar hyalinosis (an indication of cyclo-
sporine toxicity) is also scored. Principal diagnostic categories, which
can be used with or without the quantitative coding, are: (1) normal, (2)
hyperacute rejection, (3) borderline changes, (4) acute rejection (grade
Ito III), (5) chronic allograft nephropathy ("chronic rejection") (grade
Ito III), and (6) other. The goal is to devise a schema in which a given
biopsy grading would imply a prognosis for a therapeutic response or
long-term function. While the clinical implications must be proven
through further studies, the development of a standardized schema is a
critical first step. This standardized classification should promote
international uniformity in reporting of renal allograft pathology, facil-
itate the performance of multicenter trials of new therapies in renal
transplantation, and ultimately lead to improvement in the management
and care of renal transplant recipients.
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Standardization of allograft biopsy interpretation is necessary
to guide therapy in transplant patients and to help establish an
objective rejection end point in clinical trials. Stimulated by
standardization efforts in heart and lung transplantation [1, 2],
and sponsored by the International Society of Nephrology
Commission on Acute Renal Failure, a group of renal patholo-
gists, nephrologists, and transplant surgeons met in Banif,
Canada from August 2 to 4, 1991 to construct a schema for
nomenclature and classification of renal allograft pathology.
The schema underwent considerable evolution over the next
year through follow-up meetings, correspondence, and the
circulation of panel sets of biopsy slides for assessment using
schema criteria. The resulting formulation, previously reported
in abstract form [31, is described in this paper.
In the Banif schema tubulitis and intimal arteritis are re-
garded as the principal lesions indicative of acute rejection.
Although the most obvious lesion in cases of renal transplant
rejection is often interstitial infiltration by mononuclear inflam-
matory cells, five different studies in which stable kidney
transplants were biopsied have shown that focal or mild diffuse
infiltrates occur commonly in well functioning grafts [4—8]. The
presence of interstitial infiltration has a negligible effect on graft
survival [9—12]. The index patient with a biopsy heavily infil-
trated by lymphocytes illustrated in the 1984 study of Burdick et
al [6] still has normal graft function ten years later and has never
had a clinical rejection episode. D'Ardenne et al [4] found
interstitial infiltration in 80% of stable grafts on cyclosporine
therapy with diffuse infiltrates in 42%. Clearly, if interstitial
infiltration is seen in a significant proportion of well functioning
grafts, it cannot be used alone as a specific sign of rejection. It
is only when interstitial inflammation is accompanied by tubular
invasion (tubulitis) that it has any degree of specificity.
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Fig. 1. A. Representative field from one core
of a biopsy from a patient with clinically-
typical acute rejection. The core was
histologically normal and no interstitial
infiltrate was found (H&E, x 190). 8,
Representative field from second core from
same biopsy. There is a heavy interstitial
infiltrate of mononuclear inflammatory cells
(H&E, x 190).
Although it is not specific for rejection, interstitial inflamma-
tion is a typical finding in that condition, and various authors
have suggested grading severity of rejection by the extent of the
interstitial infiltrate. The objection to use of severity of inter-
stitial inflammation seen on biopsy to grade rejection relates to
sampling error. Rejection in the kidney, as in the heart [1],
begins as a patchy process. By analogy with animal models, if
one examined a cross section of the entire kidney it is likely that
there would be a good correlation between extent and intensity
of inflammation and severity of rejection [13]. However random
without rejection as mentioned above. Also rare cases of
moderate-to-severe rejection may be sampled in such a way
that an entire biopsy core may appear normal (Fig. la and b).
The degree of inifitration has no correlation with response to
therapy [5, 11, 121, probably due, at least in part, to sampling
error.
Methods
Description of the schema
sampling by a single core needle biopsy may eliminate this The formal classification is presented in Tables 1 to 4. It
correlation and interstitial infiltrates can be seen in patients includes hyperacute rejection, borderline changes, three grades
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Table 1. Diagnostic categories for renal allograft biopsies
1. Normal
2. Hyperacute rejection (see Definitions)
3. Borderline changes ("very mild acute rejection")
This category is used when no intimal arteritis is present, but only mild or moderate focal mononuclear cell infiltration with foci of mild
tubulitis (1 to 4 mononuclear cells/tubular cross section).
4. Acute rejection
Grade I, mild acute rejection
Cases with significant interstitial infiltration (> 25% of parenchyma affected) and foci of moderate tubulitis (> 4 mononuclear
cells/tubular cross section or group of 10 tubular cells).
Grade II, moderate acute rejection
Cases with (A) significant interstitial infiltration and foci of severe tubulitis (> 10 mononuclear cells/tubular cross section) and/or (B) mild
or moderate intimal arteritis.
Grade III, severe acute rejection
Cases with severe intimal arteritis and/or "transmural" arteritis with fibrinoid change and necrosis of medial smooth muscle cells. Recent
focal infarction and interstitial hemorrhage without other obvious cause are also regarded as evidence for Grade III rejection.
5. Chronic allograft nephropathy
(Glomerular and vascular lesions help define type of chronic nephropathy; new-onset arterial fibrous intimal thickening suggests the
presence of chronic rejection.)
Grade I — Mild, chronic transplant nephropathy
Mild interstitial fibrosis and tubular atrophy
Grade II — Moderate chronic transplant nephropathy
Moderate interstitial fibrosis and tubular atrophy
Grade III — Severe chronic transplant nephropathy
Severe interstitial fibrosis and tubular atrophy and tubular loss
6. Other (changes not considered to be due to rejection, see Table 3)
The recommended format of report is a descriptive narrative signout followed by numerical codes in parentheses (see Table 2). Categorization
should in the first instance be based solely on pathologic changes, then integrated with clinical data as a second step. More than one diagnostic
category may be used if appropriate.
Table 2. Numerical codes, specimen adequacy, and minimum sampling standards
Qualify diagnostic categories 3, 4, and 6 from Table 1 by g, i, t, v, and ah coding
g 0, 1, 2, 3 no, mild, moderate, severe glomerulitis (g3 = mononuclear cells in capillaries of all or
nearly all glomeruli with endothelial enlargement and luminal occlusion)
0, 1, 2, 3 no, mild, moderate, severe interstitial mononuclear cell infiltration (In rejection edema
and lymphocyte activation usually accompany mononuclear cell infiltration; i3 = >
50% of parenchyma inflamed)
0, 1, 2, 3 no, mild, moderate, severe tubulitis (t3 = > 10 mononuclear cells per tubule or per 10
tubular cells in several tubules)
v 0, 1, 2, 3 no, mild, moderate, severe intimal arteritis (v3 = severe intimal arteritis and/or
transmural arteritis and/or hemorrhage and recent infarction)
ah 0, 1, 2, 3 no, mild, moderate, severe nodular hyaline afferent arteriolar thickening suggestive of
cyclosporine toxicity (ah3 = severe PAS-positive thickening in many arterioles)
Qualify diagnostic category 5 from Table 1 by cg, ci, ct, and cv with different definitions
eg 0, 1, 2, 3 no, mild, moderate, severe chronic transplant glomerulopathy
ci 0, 1, 2, 3 no, mild, moderate, severe interstitial fibrosis, often with mononuclear cell
inflammation
ct 0, 1, 2, 3 no, mild, moderate, severe tubular atrophy and loss
cv 0, 1, 2, 3 no, mild, moderate, severe fibrous intimal thickening often with elastica fragmentation
(cv3 indicates complete occlusion); (cg and cv lesions suggest the presence of chronic
rejection)
Both acute and chronic codes can be used together if the situation warrants
Specimen adequacy (state number of glomeruli in report)
Unsatisfactory No glomeruli or arteries
Marginal 1—6 glomeruli with artery
Adequate 7 or more glomeruli with artery
Minimum sampling 7 slides with 3 H & E, 3 PAS and 1 trichrome
Table 3. Differential diagnosis: Entities in "other" category of Table 1, Changes not considered to be due to rejection
1. Post-transplant lymphoproliferative disorder—Diffuse interstitial infiltration by plasmacytoid cells
(usually atypical) with no signs of rejection in tubules, vessels, or glomeruli (usually gO,i3,tO,vO)
2. Nonspecific chnnges
— Focal interstitial inflammation without tubulitis (may be difficult to distinguish from borderline changes)
— nodular inifitrates
— perivascular infiltrates
— Vascular changes
— endothelial reactive changes
— vacuolization
— venulitis
3. Acute tubular necrosis
— Cell loss, non-replacement
— Cell necrosis
— Regenerative changes
— Interstitial edema, mild infiltrate
— Nucleated cells in the vasa recta
4. Acute interstitial nephritis (may at times be impossible to distinguish from rejection)
— Neutrophilic
— Eosinophilic/allergic
— Mononuclear cells
5. Cyclosporine associated changes, acute or chronic
— Tubular — isometric vacuolization, eosinophilic inclusions, microcalcification
— Vascular — nodular hyaline afferent arteriolar deposits, thrombotic microangiopathy, occlusive arteriolar change, medial
degeneration
— Interstitial — striped or patchy fibrosis
— Glomerular — sclerosis or ischemic collapse, juxtaglomerular apparatus hyperplasia
Subcapsular injury (surgical)
Pretransplant acute endotheial injury
Papillary necrosis
9. De novo glomerulonephritis
10. Recurrent disease
— Immune complex glomerulonephritis
— Focal sclerosis
— Diabetes
— Hemolytic-uremic syndrome
— Other
11. Pre-existing disease
— Nephrosclerosis, glomerular disease
12. Other
— Arterial or venous thrombosis
— Viral infection, CMV
— Obstruction and reflux, lymphocele, urine leak
of acute rejection, chronic aliograft nephropathy, and "other"
changes not thought to represent rejection. This classification is
very likely to change as our knowledge grows concerning
significance of pathologic changes observed. At present, for
instance, the classification does not incorporate glomerulitis
(Fig. 2) as a defining feature, since its significance as evidence
of rejection is uncertain although its presence in the first few
months post-transplant has been reported to shorten graft
survival time [14—20]. Glomerulitis as described in Table 4 is
included in the scoring system for individual pathologic fea-
tures, however (see below). The classification also groups
together under the term "chronic allograft nephropathy" at
least four entities that at present cannot always be distinguished
by biopsy (chronic rejection, chronic cyclosporine toxicity,
hypertensive vascular disease, and chronic infection and/or
reflux). New-onset fibrous intimal thickening (Fig. 3) is sugges-
tive of chronic rejection [21] if recipient hypertension can be
excluded as a cause.
In comparison with the summary classification of diagnostic
categories and grades, which may undergo evolutionary
changes, the numerical scoring system (Table 2) is less likely to
be altered with time. The scoring codes which are used to
establish rejection grades but also have independent usefulness
are designated g, i, t, v, ah, for glomerular, interstitial, tubular,
or vascular changes, and arteriolar hyalinosis, respectively, in
the acute setting. Chronic changes are scored cg, ci, ct and cv,
respectively. It would be possible to apply relative weightings
and calculate overall severity scores using this coding system.
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Table 4. Definitions
Arteritis, intimal (synonymous with endothelialitis). Intimal
thickening with inflammation of arterial subendothelial space ranging
from rare intimal inflammatory cells to necrosis of endothelium with
deposition of fibrin, platelets and inflammatory cells. The cellular
infiltrate is composed of lymphocytes and monocytes. Severity is
determined by the number of vessels affected as well as by intensity
of individual lesions. Mild degrees of intimal arteritis can be
extremely focal.
Arteritis, transmural. Injury and inflammation of the whole arterial
wall including the media, necrosis of medial smooth muscle cells,
fibrin insudation and cellular infiltration with mononuclear as well as
polymorphonuclear leukocytes.
Borderline changes. Changes which might be considered suggestive
of rejection but which are nondiagnostic (such as a moderate
interstitial mononuclear cell infiltrate with very mild tubulitis).
De novo glomerulonephritis. Glomerulonephritis in the allograft
morphologically dissimilar to the original disease and distinct from
transplant glomerulopathy or transplant glomerulitis. Presumed to be
due to etiologies similar to those responsible for native kidney
glomerulonephritis.
Hyperacute rejection. Rejection presumed to be due to preformed
antibody, usually characterized by polymorph accumulation in
glomerular and peritubular capillaries at one hour post-transplant
with subsequent endothelial damage and capillary thrombosis.
Ischemic glomerulopathy. A. Acute: glomerular capillary
engorgement and glomerular necrosis. May occur in hyperacute and
in severe acute rejection. B. Late: Thickening, wrinkling and collapse
of glomerular capillary walls associated with extracapillary fibrotic
material. May be a sequel to diffuse arterial occlusion in chronic
vascular rejection.
Recurrence. Lesions in the graft morphologically similar to the
original disease, and presumed to be due to persistence of
pathogenetic mechanism leading to end stage disease in the native
kidney, such as, diabetic glomerulopathy, recurrent
glomerulonephritis, and amyloidosis.
Transmission. Persistence of lesions which were present in the
transplanted kidney before transplantation, such as,
glomerulonephritis. This should not be mistaken for recurrence.
Transplant glomerulopathy. Immunologic glomerular damage due to
transplant antigens. A. Early form (glomerulitis): Endocapillary
accumulation of lymphocytes and monocytes with endothelial cell
swelling. B. Late form (syn. chronic transplant glomerulopathy):
Mesangial cell proliferation, peripheral mesangial interposition and
sometimes cellular crescents. The late form is usually associated with
marked proteinuria, often in the nephrotic range. Should be
distinguished from ischemic glomerular change, recurrent
glomerulonephritis and transmitted glomerulonephritis.
Tubulitis. Infiltration of tubular epithelium by leukocytes, usually
lymphocytes.
The scoring codes can also be used without the classification
system or vice versa if that is the wish of individual centers.
The classification in Table 1 combined with the differential
diagnoses ("other" categories) in Table 3 and the definitions in
Table 4 will provide a reproducible system which maximizes the
clinical utility of the biopsy. The utilization of this schema in
studies of therapeutic modalities to minimize rejection will be
an important assessment of its validity. The schema is designed
so that the false positive rate in diagnosis of rejection should be
very low. Standards for adequacy and minimum sampling and
stains are provided in Table 2. If these standards are not
followed severity of lesions may be underestimated. Owing to
the patchiness of early rejection there may be a substantial false
negative rate if only a single core of tissue containing a small
amount of cortex is examined. This diminishes considerably if
two or three cores are obtained or if there is a substantial
amount of cortex represented in a single large core.
The portion of the schema which evaluates new-onset arte-
riolar hyaline thickening (Fig. 4) as a sign of cyclosporine
nephrotoxicity assumes the presence of a baseline (implanta-
tion) biopsy or other prior negative biopsy for comparison.
Although on occasion a destructive hyalinosis characteristic of
cyclosporine toxicity may be recognized [22], arteriolar hyaline
thickening is usually of little diagnostic value in the absence of
a prior biopsy lacking this change, as it could have been present
in the donor kidney as a result of hypertension or age. This
change, which is potentially reversible [23], may also develop
independent of cyclosporine toxicity as a consequence of
diabetes or hypertension in the recipient. Similarly, some
chronic changes, such as fibrous intimal thickening and inter-
stitial fibrosis may pre-exist in kidneys from older donors [241.
The concepts of "acute" and "chronic" entities in the trans-
planted kidney may require further modification in the future.
Neither the lesions observed themselves nor the time post-
transplant are sufficient to completely define these terms. Acute
rejection may occur many years after transplantation if immu-
nosuppression is stopped. Similarly, "chronic" lesions may be
observed in an implantation or early post-transplant biopsy if
the donor has age-related vascular disease. Such lesions are a
definite indication of chronic processes in the recipient only if
they were not present in the donor.
Table 5, which contains a simplified description of the
schema, was developed recently for participants who wanted a
single page summary which would include possible clinical
response to various biopsy appearances and grades. The "pos-
sible clinical approach" column is meant only as a general
guide; it should not be taken as a recommendation for specific
therapies or approaches. Clearly individual centers will develop
their own clinical strategies for dealing with various biopsy
findings.
Despite the fact that there will be individual variations in
therapeutic approach, it is necessary to have a general under-
standing of the defining characteristics and significance of the
three grades of acute rejection.
Grade I (mild) acute rejection differs from the borderline
changes category in that it has tubulitis quantitatively more
severe than that observed in kidneys with normal function or in
ATN [511. Tubulitis severity is most easily assessed in PAS-
stained sections by examining the number of lymphocytes
present in the most inflamed tubule in an area after observing
the overall severity of interstitial inflammation and degree of
tubulitis in less affected tubules. The use of thin well stained
sections is a necessary prerequisite for this assessment to be
reliable. Quantitative criteria for tubulitis scoring are discussed
further in the section below.
In Grade II (moderate) rejection the diagnosis of rejection is
more secure because the lesions on which the diagnosis de-
pends, foci of tubulitis with >10 lymphocytes per most inflamed
tubular cross section (Fig. 5) or intimal arteritis (Fig. 6), are
highly specific for rejection. Cases with this grade of rejection
are likely to behave more aggressively than those in Grade I.
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Fig. 2. A. Example of glomerulitis showing accumulation of mononuclear inflammatory cells in glomerular capillaries. Tubulitis is also seen at
lower right (PAS, x 120). B. Another example of glomerulitis showing extensive capillary occlusion by endothelial swelling and accumulation of
monocytes (PAS, x 120).
Fig. 3. Fibrous intimal thickening in a patient with chronic rejection
(Masson trichrome stain, x 57).
In Grade III (severe) rejection the process is so aggressive
that highly potent antirejection therapies need to be considered,
as well as the possibility that the rejection process may not be
reversible. Necrotizing vascular changes (Fig. 6C) suggest
irreversible rejection, and are most commonly observed only in
nephrectomy specimens.
Quantitative criteria for lesion severity
Preliminary results assessing panel slides with the use of the
Banff schema indicate an 82% agreement on diagnosis of
rejection [25]. The panel slide assessments, which will be
reported separately, led to the development of quantitative
criteria for lesion severity (Tables 6 to 10). These criteria
represent a compromise between a formal morphometric as-
sessment of these lesions and a fully qualitative approach. Our
experience with the panel slides also resulted in the recommen-
dation that PAS stains be used to assess tubulitis, glomerulitis,
and arteriolar hyaline thickening.
In the tubulitis scoring (Table 6) it is important to differentiate
lymphocytes from apoptotic tubular cells (Fig. 7). Lympho-
cytes between or beneath tubular cells are often surrounded by
a clear space and have an appearance similar to lymphocytes
seen in the surrounding interstitium. The t 1 designation is used
for the very mild tubulitis, below the threshold for diagnosis of
rejection, which can be observed in the normally functioning
kidney or ATN [5]. The manner in which tubulitis and intimal
arteritis are used to establish a diagnosis of rejection of various
seventies is shown in Tables 1 and 5: mild (t 1) tubulitis =
borderline changes, moderate (t 2) tubulitis = mild (grade I)
rejection, and severe (t 3) tubulitis = moderate (grade II)
rejection, mild to moderate (v 1 or 2) intimal arteritis =
moderate rejection, and severe (v 3) intimal arteritis = severe
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Fig. 4. Nodular hyaline arteriolar thickening
(PAS, x 550).
Table 5. The Banif schema simplified
Biopsy findings Banif classification Possible clinical approach
Normal, minor changes, or
infiltrates without tubular
invasion
Normal or "other" (non-specific
changes)
No treatment, or treat other entity
Mild lymphocytic invasion of
tubules (tubulitis)
Borderline changes No treatment, or treat other entity
Widespread interstitial infiltrate
with moderate invasion of
tubules
Mild acute rejection (Grade I) Treat for rejection if there are
clinical signs
(A) Widespread interstitial infiltrate
with severe invasion of tubules
and/or (B) mild or moderate
intimal arteritis
Moderate acute rejection (Grade II) Treat for rejection, consider ALG/
OKT3 if refractory to steroids
Severe intimal arteritis and/or
"transmural" arteritis, fibrinoid
change, and medial smooth
muscle cell necrosis often with
patchy infarction and interstitial
hemorrhage
Severe acute rejection (Grade III) Treat for rejection unless clinical
course suggests rejection cannot
be reversed in which case
consider abandoning the graft
Hyaline arteriolar thickening (new
onset, not present in
implantation biopsy), and/or
extensive isometric vacuolization
of tubules, smooth muscle
degeneration, thrombotic
microangiopathy.
"Other", cyclosporine toxicity Reduce cyclosporine therapy
Tubular cell loss and necrosis,
regenerative changes
"Other", acute tubular necrosis Await recovery
Interstitial fibrosis, tubular atrophy
(new onset arterial fibrous
intimal thickening suggests
chronic rejection)
Chronic transplant nephropathy Temporize
The detailed version of the Banif Schema outlined in Tables 1 to 4 and described in the text is designed to address all circumstances that might
be encountered. However, the simplified schema above will suffice for many common biopsy appearances.
rejection. The interstitial inflammation scoring (Table 7) evalu- Discussion
ates extent of parenchymal infiltration rather than intensity
(which is to some extent indirectly evaluated in the tubulitis Unlike the heart transplant formulation [1, 26], the schema
scoring), for the kidney employs the term "rejection" only for those
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Fig. 5. A. Tubulitis. Note the clear spaces that usually separate lymphocyte nuclei (arrows) from adjacent tubular cells (PAS, X 281). There is a
tubule (center) in which the number of infiltrating lymphocytes exceeds ten consistent with severe tubulitis (T 3). B. Another example of severe
tubulitis. The tubule to the left (double arrow) can be used for grading, but the one on the right (single arrow) which has lost itsbasement
membrane, cannot (PAS, x 170).
Table 6. Quantitative criteria for tubulitis ("t") score (Q—3+)
(assumes that minimum sampling standards in
Table 2 are adhered to.)
0 No mononuclear cells in tubules
= Foci with 1 to 4 cells/tubular cross section or 10 tubular cells
2 = Foci with 5 to 10 cells/tubular cross section
3 = Foci with >10 cells/tubular cross section
Table 9. Quantitative criteria for arteriolar hyaline thickening ("ah")
(0 to 3+)
0 = No PAS-positive hyaline thickening
= Mild-to-moderate PAS-positive hyaline thickening in at least one
arteriole
2 Moderate-to-severe PAS-positive hyaline thickening in more than
one arteriole
3 = Severe PAS-positive hyaline thickening in many arterioles
Table 7. Quantitative criteria for mononuclear cell interstitial
inflammation ("i") (0 to 3+)
0 = No or trivial interstitial inflammation
= up to 25% of parenehyma inflamed
2 = 26 to 50% of parenchyma inflamed
3 >50% of parenchyma inflamed
Table S. Quantitative criteria for the eariy type of allograft
glomerulitis ("g") (0 to 3+)
Accumulation of monocytes and lymphocytes in glomerular
capillaries with endothelial swelling
0 = No glomerulitis
= Glomerulitis in a minority of glomeruli
2 = Segmental or global glomerulitis in about 25 to 75% of glomeruli
3 = (ilomerulitis (mostly global) in all or almost all glomeruli
-
conditions likely to be treated with increased immunosuppres-
sion. Thus "grade 1 rejection" in the heart schema, which
would not be treated, would correspond to the "borderiine
changes" category in the Banif formulation. Clearly, the differ-
entiation of borderline changes from mild rejection is a crucial
part of the Banff schema, since it may mean the difference
between not treating and treating an episode of reduced renal
Table 10. Quantitative criteria for intimal arteritis ("v") (0 to 3+)
0 No arteritis
= Mild-to-moderate intimal arteritis in at least one arterial cross
section
2 = Moderate-to-severe intimal arteritis in more than one arterial
cross section
3 = Severe intimal arteritis in many arterial cross sections and/or
"transmural" arteritis, fibrinoid change and medial smooth
muscle necrosis, often with patchy infarction and interstitial
hemorrhage
function with increased immunosuppression. It is important to
factor in considerations relating to sampling error, time from
onset of rejection to biopsy, and the effect of anti-rejection
treatment in the final evaluation of biopsy appearances. It is
possible that eventually immunophenotyping of lymphocytes
[such as CD57 (Leu 7) staining of intratubular lymphocytes] and
especially immunophenotyping of activated lymphocytes by
activation markers (IL2R, perform, granzyme B, and class II
HLA antigen staining) will be used to fine-tune the distinction
between borderline changes and rejection [27—37].
In most centers patients will not be treated for rejection
unless they have clinical signs (allograft dysfunction) suggesting
this diagnosis, regardless of the biopsy findings observed.
Patients with persisting allograft failure from time of transplan-
tation (delayed graft function) will, however, have to be diag-
nosed and treated largely on the basis of biopsy appearance,
Fig. 6. A. Intimal arteritis typical of acute rejection sectioned in
transverse section. Endotheial cells (arrows) can be seen overlying
the lymphocytic mass in the thickened intima (H&E, x 201). B.
Severe intimal arteritis in cross section showing lymphocytes under
the endothelium and focally penetrating the media (H&E, x 360). C.
Severe transmural arteritis with fibrinoid change (H&E, x 170).
Fig. 7. Tear drop-shaped apoptotic tubular cell (arrow) in the process
of being extruded into the lumen between two normal cells in a renal
allograft biopsy. The cell has condensed, granular, PAS-positive cyto-
plasm. The apparent bare nuclei seen in the lumen of other tubules may
represent a later stage of apoptosis. Extensive apoptosis is sometimes
observed by electron microscopy in transplant biopsies [53]. Apoptosis
is unlikely to be confused with tubulitis as long as one insists that
tubulitis lymphocytes be located beneath or between tubular cells and
have an appearance similar to lymphocytes in the interstitium (PAS, x
554).
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since the allograft dysfunction observed clinically could be due
to acute tubular necrosis, acute rejection, cyclosporine neph-
rotoxicity, or a combination of these.
Rejection has more reliable clinical signs in the kidney once
allograft function commences than it does in the heart. In this
setting changes in renal function are a relatively sensitive
indicator of kidney allograft rejection, whereas changes in
cardiac function occur only in late stages of heart allograft
rejection. For this reason it may not be reasonable to make a
diagnosis of rejection in the functioning kidney transplant solely
on histologic grounds, whereas biopsy evidence alone must
frequently be used in the heart and other functioning solid organ
transplants in which rejection is often clinically silent. Reports
in the heart of persistent histologic evidence of rejection with-
out evidence of graft dysfunction [381 underscore the great
advantage of working with an organ like the kidney in which
both functional and structural data can be used together in
many instances to make a secure diagnosis of rejection. On the
other hand, elevation of serum creatinine may prove to be too
insensitive an indicator of rejection. Future studies may show
that prolongation of graft survival results if the "subclinical"
rejection represented by the borderline changes category in the
present classification is treated with increased immunosuppres-
sion.
The Banif schema is based on the concept that the degree of
lymphocytic invasion of tubules (tubulitis) is a better measure
of severity of rejection than the intensity or extent of interstitial
lymphocytic infiltration (Introduction). Tubulitis is a typical
feature of acute rejection [39-41]. Analysis of protocol biopsies
from patients with stable function or acute tubular necrosis [5]
shows that very mild tubulitis may occur in these settings (up to
4 lymphocytes per most affected tubule). However, more
intensive tubulitis is relatively specific for rejection (unpub-
lished observations). Immunophenotyping of lymphocytes in-
vading tubules may provide even greater specificity [27—371.
Intimal arteritis is the pathognomonic lesion of acute rejec-
tion, as first noted by Dammin [42]. The biologic and diagnostic
significance of this lesion in acute cell mediated rejection is well
established [6, 9, 43—46].
Most biopsies contain only two or three arterial cross sec-
tions so it is easy for all observers to concentrate on exactly the
same fields in their assessment of intimal arteritis in an individ-
ual case. In contrast a single biopsy section may contain several
hundred tubular cross sections. If the biopsy is diffusely infil-
trated it becomes a matter of chance whether two observers
concentrate on the same microscopic fields in assessment of
tubulitis. Devising a more accurate and reproducible method for
assessing tubulitis which is still practical and time-efficient
remains one of our goals for the future.
An interstitial infiltrate of polymorphonuclear leukocytes as a
feature of acute rejection has not been dealt with specifically in
the present schema. Polymorphs and eosinophils are sometimes
present in the interstitial infiltrate of acute rejection. Pure
polymorph infiltrates occur at the periphery of recent infarcts
and may therefore be seen in cases with arteritis and infarction.
They may also be observed in cases of antibody-mediated
rejection [47, 48] and are particularly likely to be seen in
ABO-incompatible grafts.
Concerns about inaccuracy due to sampling error led Rapa-
port, Converse and Billingham to state in 1977 that "percuta-
neous renal biopsy of renal transplants has been generally
abandoned because rejection injury is not distributed uniformly
throughout the transplanted kidney" [49]. Although the demise
of the renal allograft biopsy did not occur, the sampling error
considerations noted by Rapaport are still important today. As
Sanfilippo has emphasized, "healing in" of the graft may lead to
a subcapsular infiltrate unrelated to rejection [50]. Substantial
interstitial inifitrates may also be found in non-rejecting grafts in
the mid-to-deep cortex [4-8]. Although experimental studies
[51, 521 have indicated that serious sampling error with percu-
taneous biopsies is likely to be infrequent, such error neverthe-
less occurs and must be taken into account in biopsy interpre-
tation.
In conclusion, we have presented a formulation for the
evaluation of rejection and other conditions in renal allograft
biopsies. We feel that it can be applied reliably to diagnose and
grade rejection as long as criteria of minimum sampling and
specimen adequacy are met. The schema presented is an
important step in the design of effective multicenter trials and in
the study of the clinical significance of lesions observed on
biopsy. This classification has already been adopted for inter-
national multicenter trials of four new immunosuppressive
agents (RS61443, Cyclosporin 0, brequinar, and anti-CD4S),
and should lead to international uniformity in evaluation of
biopsy findings in many centers currently performing renal
transplantation. The numerical coding of specific biopsy fea-
tures, in particular, should contribute in a major way to
objective data assessment and statistical analysis. The ultimate
hope is that such a classification will lead to major improve-
ments in patient care and management.
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